Mesalazine probiotics combined efficacy of treatment of ulcerative colitis.doc

 PAGE \* MERGEFORMAT 15 Mesalazine probiotics combined efficacy of treatment of ulcerative colitis [Keywords:] ulcerative colitis, probiotics, mesalazine Ulcerative colitis (ulceration colitis, UC) is a group of unknown cause non-specific inflammatory bowel disease to chronic process, its characteristics automatically recurrence. Were mostly young adults, very common in Western countries. In recent years as people improvement of living standards, UC incidence of the number increasing year by year in China, based on the number of hospital case statistics inference, the prevalence was 11.6/10 million [1]. At present the disease has become a common digestive diseases and a major cause of chronic diarrhea . Ulcerative colitis (UC) in the treatment of inflammation and regulation of immune responses to the main. Recent studies have found that severe intestinal flora is closely related with the UC, so the research and application of probiotics and more attention. Probiotic bacterial microbial agents as a new therapy for the treatment of ulcerative colitis beyond the traditional use of 5-ASA, corticosteroids and immunosuppressive therapy. a lot of probiotics appear to be safe and effective treatment effect, especially with the traditional treatment effect is more obvious when used simultaneously. Probiotics assist our department with mesalazine therapy in patients with UC and to observe the clinical efficacy, clinical data now reported as follows. 1 Subjects and methods 1.1 Case Select from June 2005 to June 2008 in our hospital clinical diagnosis of early onset, chronic relapsing active stage of mild to moderate ulcerative colitis patients with a total of 34 cases, 20 cases were randomly divided into treatment group and control group 14 cases. the treatment group 13 males and 7 females, aged 19 to 56 years, average 38.2 years, duration of six months to 15 years, first made in 8 cases, 12 cases of recurrence. control group, 9 males and 5 females,